Skip to content

CELG-RI

BRISTOL MYERS SQUIBB CO

NYSE · Healthcare · Drug Manufacturers - General · US

$0.12
+1.19%
Ask drillr

Income statement

MetricTTM2025202420232022
Revenue
Total Revenue49.2B48.2B48.3B45.0B46.2B
Cost of Revenue15.5B16.4B20.9B10.7B10.1B
Gross Profit33.7B31.8B27.4B34.3B36.0B
Operating Expenses
R&D Expense10.2B9.5B11.2B9.3B9.5B
SG&A Expense7.3B7.1B7.9B7.8B7.8B
General & Admin Expense6.4B
Selling & Marketing Expense1.5B7.8B
Other Expenses813.0M(1.3B)9.0B9.6B
Total Operating Expenses18.3B16.6B17.8B26.1B26.9B
Cost and Expenses33.8B33.1B38.6B36.8B37.1B
Operating Income (EBIT)15.3B15.1B9.7B8.2B9.1B
Non-Operating
Interest Income413.0M586.0M
Interest Expense1.7B1.9B1.9B1.2B1.2B
Net Interest Income(1.3B)(1.3B)(1.9B)(1.2B)(1.2B)
Other Non-Op Income/Expense(3.4B)(5.8B)(18.0B)245.0M(1.4B)
Non-Operating Income (excl Interest)(407.0M)16.1B(1.4B)159.0M
EBT (Pre-Tax Income)11.9B9.3B(8.4B)8.4B7.7B
Income Tax Expense2.6B2.3B554.0M400.0M1.4B
Bottom Line
Net Income9.3B7.1B(8.9B)8.0B6.3B
Earnings from Cont. Ops9.3B7.1B(8.9B)8.0B6.3B
Earnings from Discont. Ops
Bottom Line Net Income9.3B7.1B(8.9B)8.0B6.3B
Per Share
Basic EPS$4.54$3.47($4.41)$3.88$2.97
Diluted EPS$4.54$3.46($4.41)$3.86$2.95
Revenue Per Share$24.09$23.69$23.83$21.75$21.67
Shares
Basic Shares Outstanding2.0B2.0B2.0B2.1B2.1B
Diluted Shares Outstanding2.0B2.0B2.0B2.1B2.1B
Profitability Metrics
EBITDA18.3B19.2B3.2B19.4B19.2B
D&A2.5B4.1B9.6B9.8B10.3B
EBIT15.7B15.1B(6.4B)9.6B8.9B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026